During the 2025 International Forum on Gonococcal Infections and Resistance (IFGIR) from October 17 to 19 in Hangzhou, China, Shuwen Biotech presented its vision and technological breakthroughs in gonococcal drug resistance detection, offering a solution for global antimicrobial resistance (AMR) response.

As a leading academic forum for global gonococcal infection and resistance research, this year’s IFGIR brought together over 100 experts and scholars from worldwide in gonococcal diagnosis, treatment and prevention. Attendees engaged in in-depth discussions on challenges and technological innovations in AMR response.

Gonococcal AMR has become a major threat to global public health, severely undermining the effectiveness of clinical treatments. Compared to the traditional culture methods that require a few days of wait time, Shuwen’s screening technology for drug-resistant infection is based on its new mutation discoveries and innovative algorithms, and can deliver test results within one or two hours.

“Once implemented, this technology will fundamentally transform the current state of gonococcal AMR testing, which has long been plagued by long turnaround time, low accuracy, and limited coverage,” commented Dr. Barclay Li, Shuwen’s Chief Scientific Officer.  “Our technology would allow physicians to identify the pathogen’s drug resistance profile and select the most suitable antibiotic treatment regimen right at the initial consultation.  This not only prevents the exacerbation of resistance caused by trial and error in medication use, but also provides real-time, accurate data support for AMR surveillance networks.”  Shuwen is advancing this patented technology toward clinical translation and international collaboration.